Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required?

Forthal D, Finzi A.

J Clin Invest. 2019 Jan 2;129(1):53-54. doi: 10.1172/JCI125264. Epub 2018 Nov 26.

2.

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R.

J Virol. 2019 Jan 17;93(3). pii: e01529-18. doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.

3.

Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL.

J Virol. 2019 Jan 17;93(3). pii: e01513-18. doi: 10.1128/JVI.01513-18. Print 2019 Feb 1.

4.

Antibody-dependent cellular cytotoxicity in HIV infection.

Forthal DN, Finzi A.

AIDS. 2018 Nov 13;32(17):2439-2451. doi: 10.1097/QAD.0000000000002011.

PMID:
30234611
5.

HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition.

Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G.

Nat Med. 2018 Jun;24(6):847-856. doi: 10.1038/s41591-018-0025-7. Epub 2018 May 21.

6.

Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.

Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal DN.

PLoS Pathog. 2017 Dec 27;13(12):e1006793. doi: 10.1371/journal.ppat.1006793. eCollection 2017 Dec.

7.

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J.

J Virol. 2018 Jan 2;92(2). pii: e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15.

8.

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME.

J Immunol. 2016 Dec 15;197(12):4603-4612. Epub 2016 Nov 9.

9.

Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192a. No abstract available.

PMID:
27711066
10.

Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition.

Gordon SN, Liyanage NP, Doster MN, Vaccari M, Vargas-Inchaustegui DA, Pegu P, Schifanella L, Shen X, Tomaras GD, Rao M, Billings EA, Schwartz J, Prado I, Bobb K, Zhang W, Montefiori DC, Foulds KE, Ferrari G, Robert-Guroff M, Roederer M, Phan TB, Forthal DN, Stablein DM, Phogat S, Venzon DJ, Fouts T, Franchini G.

J Immunol. 2016 Oct 1;197(7):2726-37. doi: 10.4049/jimmunol.1600674. Epub 2016 Sep 2.

11.

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, Felgner PL, Forthal DN, Deeks SG, Wilkin TJ, Casazza JP, Koup RA, Katlama C, Autran B, Murphy RL, Achenbach CJ.

PLoS One. 2016 Aug 8;11(8):e0160341. doi: 10.1371/journal.pone.0160341. eCollection 2016.

12.

Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Gach JS, Venzon D, Vaccari M, Keele BF, Franchini G, Forthal DN.

J Virol. 2016 Sep 12;90(19):8487-95. doi: 10.1128/JVI.00812-16. Print 2016 Oct 1.

13.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Loré K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G.

Nat Med. 2016 Jul;22(7):762-70. doi: 10.1038/nm.4105. Epub 2016 May 30. Erratum in: Nat Med. 2016 Oct 6;22(10 ):1192.

14.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.

J Virol. 2016 Mar 28;90(8):4133-4149. doi: 10.1128/JVI.03135-15. Print 2016 Apr.

15.

Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE Jr.

Mol Immunol. 2016 Feb;70:94-103. doi: 10.1016/j.molimm.2015.12.002. Epub 2015 Dec 31.

16.

HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.

Williams KL, Cortez V, Dingens AS, Gach JS, Rainwater S, Weis JF, Chen X, Spearman P, Forthal DN, Overbaugh J.

EBioMedicine. 2015 Oct;2(10):1464-77.

17.

Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.

Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12675-80. doi: 10.1073/pnas.1509090112. Epub 2015 Sep 28.

18.

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.

Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF.

PLoS Pathog. 2015 Aug 3;11(8):e1005042. doi: 10.1371/journal.ppat.1005042. eCollection 2015 Aug.

19.

Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein.

Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE Jr.

PLoS One. 2015 Jul 30;10(7):e0133509. doi: 10.1371/journal.pone.0133509. eCollection 2015.

20.

Functions of Antibodies.

Forthal DN.

Microbiol Spectr. 2014 Aug;2(4):AID-0019-2014. doi: 10.1128/microbiolspec.AID-0019-2014. Review.

PMID:
26104200
21.

A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.

Dotsey EY, Gorlani A, Ingale S, Achenbach CJ, Forthal DN, Felgner PL, Gach JS.

PLoS One. 2015 May 4;10(5):e0125581. doi: 10.1371/journal.pone.0125581. eCollection 2015.

22.

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM.

Vaccine. 2015 Apr 21;33(17):2086-95. doi: 10.1016/j.vaccine.2015.02.020. Epub 2015 Mar 11.

23.

Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM.

Chromikova V, Mader A, Hofbauer S, Göbl C, Madl T, Gach JS, Bauernfried S, Furtmüller PG, Forthal DN, Mach L, Obinger C, Kunert R.

Biochim Biophys Acta. 2015 Oct;1854(10 Pt A):1536-44. doi: 10.1016/j.bbapap.2015.02.018. Epub 2015 Mar 5.

24.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Lakhashe SK, Byrareddy SN, Zhou M, Bachler BC, Hemashettar G, Hu SL, Villinger F, Else JG, Stock S, Lee SJ, Vargas-Inchaustegui DA, Cofano EB, Robert-Guroff M, Johnson WE, Polonis VR, Forthal DN, Loret EP, Rasmussen RA, Ruprecht RM.

Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20.

25.

Functions of Antibodies.

Forthal DN.

Microbiol Spectr. 2014 Aug 15;2(4):1-17. No abstract available.

26.

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.

27.

Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN.

J Infect Dis. 2015 Jan 1;211(1):45-52. doi: 10.1093/infdis/jiu300. Epub 2014 May 21.

28.

HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.

Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL.

PLoS One. 2014 Jan 15;9(1):e85371. doi: 10.1371/journal.pone.0085371. eCollection 2014.

29.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

30.

The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN.

PLoS Pathog. 2013;9(11):e1003776. doi: 10.1371/journal.ppat.1003776. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Nov;9(11). doi:10.1371/annotation/31430955-703b-484a-96eb-e180f917d683.

31.

Antibody-dependent enhancement and the risk of HIV infection.

Gorlani A, Forthal DN.

Curr HIV Res. 2013 Jul;11(5):421-6. Review.

PMID:
24191936
32.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

33.

New paradigms for functional HIV-specific nonneutralizing antibodies.

Forthal D, Hope TJ, Alter G.

Curr Opin HIV AIDS. 2013 Sep;8(5):393-401. doi: 10.1097/COH.0b013e328363d486. Review.

34.

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL.

J Virol. 2013 Oct;87(19):10447-59. doi: 10.1128/JVI.00049-13. Epub 2013 Jul 24.

35.

Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.

Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM; CAVD Project Group.

AIDS. 2013 Jun 1;27(9):F13-20. doi: 10.1097/QAD.0b013e328360eac6.

36.

Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems.

Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X.

PLoS One. 2013;8(3):e58724. doi: 10.1371/journal.pone.0058724. Epub 2013 Mar 22.

37.

Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.

Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):31-3. doi: 10.1097/QAI.0b013e3182874d41.

38.

Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G.

J Virol. 2013 Mar;87(6):3538-48. doi: 10.1128/JVI.02863-12. Epub 2013 Jan 16.

39.

Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB.

Blood. 2012 Oct 4;120(14):2836-42. doi: 10.1182/blood-2012-05-431361. Epub 2012 Aug 22.

40.

In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds.

Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H, Elofsson M, Peterson E.

Int J Antimicrob Agents. 2012 Oct;40(4):354-60. doi: 10.1016/j.ijantimicag.2012.05.023. Epub 2012 Jul 20.

41.

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K.

Retrovirology. 2012 Jul 17;9:57. doi: 10.1186/1742-4690-9-57.

42.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

43.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

44.

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

McBurney SP, Landucci G, Forthal DN, Ross TM.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72. doi: 10.1089/AID.2011.0351. Epub 2012 Mar 21.

45.

Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G.

Vaccine. 2011 Dec 9;30(1):78-94. doi: 10.1016/j.vaccine.2011.10.040. Epub 2011 Oct 27.

46.

High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.

Rasmussen RA, Siddappa NB, Lakhashe SK, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-Guroff M, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM; Clade C Program Project Group.

AIDS. 2012 Jan 14;26(2):149-55. doi: 10.1097/QAD.0b013e32834d3c4f.

47.

IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.

Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T.

AIDS. 2011 Nov 13;25(17):2099-104. doi: 10.1097/QAD.0b013e32834b64bd.

PMID:
21832933
48.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

49.

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL.

Nat Med. 2010 Oct;16(10):1117-9. doi: 10.1038/nm.2233. Epub 2010 Oct 3.

50.

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF.

J Exp Med. 2010 Apr 12;207(4):763-76. doi: 10.1084/jem.20091281. Epub 2010 Apr 5.

Supplemental Content

Loading ...
Support Center